Background. To describe the existing pharmacological managements for Multisystem
Inflammatory Syndrome in Children (MIS-C) in a systematic way, to identify the available …

Background Multisystem inflammatory syndrome in children (MIS-C), a relatively uncommon
but severe pediatric complication, is associated with coronavirus disease 2019 (COVID-19) …

Objective: The purpose of this study was to map and describe the studies that have
investigated therapeutic alternatives for the management of paediatric multisystem …

Background Evidence is urgently needed to support treatment decisions for children with
multisystem inflammatory syndrome (MIS-C) associated with severe acute respiratory …

Background: Multisystem inflammatory syndrome in children (MIS-C) is an uncommon but
serious condition that occurs in association with the coronavirus disease 2019 infection in …

Introduction and aim Knowledge about multisystem inflammatory syndrome in children (MIS-
C) is still evolving, and evidence-based standardized diagnostic and management protocols …

Background Knowledge about multisystem inflammatory syndrome in children (MIS-C) is
evolving, and evidence-based standardised diagnostic and management protocols are …

Abstract Background Multisystem Inflammatory Syndrome in Children (MIS-C), which occurs
2–6 weeks after initial exposure to SARS-CoV-2, was first identified in early 2020 when …

Within 6 months of the coronavirus pandemic, a new disease entity associated with a
multisystem hyperinflammation syndrome as a result of a previous infection with the SARS …

Objective Two cohort studies in patients with multisystem inflammatory syndrome in children
(MIS‐C) demonstrated contrasting results regarding the benefit of initial immunomodulatory …